AORT Earnings Prediction
The chart below shows how AORT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AORT sees a -1.13% change in stock price 10 days leading up to the earnings, and a +7.80% change 10 days following the report. On the earnings day itself, the stock moves by +0.01%. This data can give you a slight idea of what to expect for the next quarter's release.
AORT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
95.78M
9.02%
-2.29%
Gross Margin
63.70%
-0.55%
-1.39%
Operating Margin
8.13%
38.50%
-6.34%
Net Margin
-2.39%
-78.58%
10.65%
EPS
-0.05
-79.17%
-0.00%
No Data Available
AORT Earnings Analysis
Artivion, Inc. Corporation (AORT.N) Earnings Conference Call
Positive
Strong Revenue Performance: 1. Robust Revenue Growth: Artivion reported a 10% year-over-year constant currency revenue growth, achieving $95.8 million in revenue for Q3 2024.
EBITDA Growth Surge: 2. Significant EBITDA Increase: Adjusted EBITDA grew by 28% year-over-year, rising from $13.9 million to $17.7 million in Q3 2024, with an adjusted EBITDA margin improvement of 270 basis points.
Product Revenue Growth: 3. Strong Product Performance: On-X revenues increased by 15%, BioGlue grew by 14%, and stent graft revenues rose by 13% year-over-year on a constant currency basis in Q3 2024.
International Revenue Growth: 4. International Market Expansion: Revenue growth in Latin America and Asia Pacific was impressive, with increases of 32% and 23% respectively compared to Q3 2023.
Regulatory Approval Anticipation: 5. Positive Regulatory Developments: The company filed the first module of the PMA application for AMDS with the FDA, anticipating a $150 million U.S. market opportunity upon approval in Q4 2025.
Negative
Other Revenue Decline: 1. Decline in Other Revenue: Other revenue decreased by approximately $561,000, or 17%, in Q3 2024 due to the timing of PerClot orders from Baxter, which is expected to continue affecting revenue through the end of 2024.
Tissue Processing Revenue Slowdown: 2. Tissue Processing Growth Below Expectations: Tissue processing revenue growth was only 2% year-over-year in Q3 2024, attributed to lower-than-anticipated donor allograft volumes, indicating a slowdown in this segment.
Rising Interest Expenses: 3. Increased Interest Expense: Interest expense net of interest income rose to $8 million in Q3 2024, up from $6.3 million in the prior year, reflecting higher borrowing costs that could impact profitability.
Gross Margin Stability: 4. Flat Gross Margins: Gross margins remained flat at 64% in Q3 2024 compared to the same quarter in 2023, suggesting no improvement in cost management or pricing power despite revenue growth.
Convertible Debt Classification: 5. Convertible Debt Moved to Current: The company's convertible debt moved to current on the balance sheet, indicating potential liquidity concerns as it may require cash or shares for settlement by July 2025.
AORT FAQs
How does AORT typically perform around its earnings report dates?
Is Artivion, Inc. (AORT) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AORT Earning Call Sentiment
Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
AORT.N
0.48%Positive
The earnings call summary shows strong financial performance, with revenue and EBITDA growth, improved leverage, and positive cash flow. The raised guidance for revenue and EBITDA further supports optimism. While there are risks like supply chain challenges and competitive pressures, the Q&A reveals confidence in product growth and market share gains. The market cap indicates a potential stock price increase of 2% to 8% over the next two weeks, driven by positive sentiment and strong financial metrics.